IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)
Zhu, Xuejun1; Zheng, Min2; Song, Michael3; Shen, Yaung-Kaung4; Chan, Daphne3; Szapary, Philippe O.3; Wang, Baoxi5; LOTUS Investigators
刊名JOURNAL OF DRUGS IN DERMATOLOGY
2013-02-01
12期:2页:166-174
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Dermatology
资助者Janssen Research &amp ; Development, LLC. ; Janssen Research Development ; Janssen Research &amp ; Development, LLC. ; Janssen Research Development
研究领域[WOS]Dermatology
关键词[WOS]PLACEBO-CONTROLLED TRIAL ; TO-SEVERE PSORIASIS ; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY ; LATENT TUBERCULOSIS INFECTION ; DOUBLE-BLIND TRIAL ; HAN POPULATION ; FOLLOW-UP ; THERAPY ; POLYMORPHISMS ; MULTICENTER
英文摘要

Background: Available biologic agents for the treatment of psoriasis in China are limited.

Objectives: The LOTUS study is a phase 3, double-blind, placebo-controlled study that evaluated the efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis.

Patients and Methods: Patients (n=322) were randomized to receive ustekinumab 45 mg or placebo at weeks 0 and 4, with placebo crossover to ustekinumab at week 12; all patients were followed up to week 36. The primary end point was the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12. Other end points at week 12 included the proportion of patients with a Physician′s Global Assessment (PGA) score of 0 or 1 and the change in Dermatology Life Quality Index (DLQI) score from baseline.

Results: At week 12, 82.5% of ustekinumab-treated patients achieved PASI 75 responses compared with 11.1% of placebo-treated patients (P<.001). Clinical responses were maintained through week 28, with maximum responses observed at week 24. Significant improvements in PGA and DLQI were observed at week 12 and were generally maintained through week 28. At week 12, adverse events rates were similar between groups (45 mg: 42.5% vs placebo: 38.5%), and serious adverse events were reported in 0.6% of patients in each group. Through week 36, no cases of active tuberculosis, serious infections, malignancies, or major adverse cardiovascular events were reported.

Conclusions: Consistent with results previously reported in global phase 3 studies, ustekinumab was highly effective and generally well tolerated in Chinese patients with moderate to severe psoriasis through 36 weeks. J Drugs Dermatol. 2013;12(2):166-174.

语种英语
资助者Janssen Research &amp ; Development, LLC. ; Janssen Research Development ; Janssen Research &amp ; Development, LLC. ; Janssen Research Development
WOS记录号WOS:000314625700006
引用统计
被引频次:20[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53818
专题北京大学第一临床医学院
作者单位1.Peking Univ, Hosp 1, Dept Dermatol & Venerol, Beijing 100871, Peoples R China
2.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Dermatol & Venerol, Hangzhou 310003, Zhejiang, Peoples R China
3.Janssen Res & Dev LLC, Dept Immunol, Spring House, PA USA
4.Janssen Res & Dev LLC, Dept Biostat, Spring House, PA USA
5.Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China
推荐引用方式
GB/T 7714
Zhu, Xuejun,Zheng, Min,Song, Michael,et al. Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)[J]. JOURNAL OF DRUGS IN DERMATOLOGY,2013,12(2):166-174.
APA Zhu, Xuejun.,Zheng, Min.,Song, Michael.,Shen, Yaung-Kaung.,Chan, Daphne.,...&LOTUS Investigators.(2013).Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS).JOURNAL OF DRUGS IN DERMATOLOGY,12(2),166-174.
MLA Zhu, Xuejun,et al."Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque-type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)".JOURNAL OF DRUGS IN DERMATOLOGY 12.2(2013):166-174.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhu, Xuejun]的文章
[Zheng, Min]的文章
[Song, Michael]的文章
百度学术
百度学术中相似的文章
[Zhu, Xuejun]的文章
[Zheng, Min]的文章
[Song, Michael]的文章
必应学术
必应学术中相似的文章
[Zhu, Xuejun]的文章
[Zheng, Min]的文章
[Song, Michael]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。